PARG is a next-generation DDR target with significant potential in PARP inhibitor-resistant cancers Preclinical data show ...

The combination of talazoparib and enzalutamide demonstrated a statistically significant improvement in radiographic ...

Collapsing the very-low-risk category reflects broader acceptance of active surveillance for Gleason 6 disease, while PARP ...

Image: Proliferating cells in a tumour organoid of triple-negative breast cancer. Credit: Dr Rebecca Marlow, The Institute of Cancer Research, London. Researchers at The Institute of Cancer Research, ...

Scientists have uncovered a hidden reason why cancer treatments don’t work equally well for everyone. Certain drugs can ...

Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...

Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved ...

Of the mCRPC patients studied, 51.2% received a PARP inhibitor. In addition, patients who are covered by commercial insurance are significantly less likely to receive PARP inhibitors than those ...